Zhao et al. conducted a phase II randomized controlled trial in China to evaluate the efficacy and safety of oral ivarmacitinib (SHR0302), a highly selective JAK-1 inhibitor with a mild JAK2-inhibiting effect (Figure 3b) in patients with moderate to severe AD. The gene discussed is JAK2; the disease is Alzheimer disease.